Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study
- 8 April 2005
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 149 (4), 650-656
- https://doi.org/10.1016/j.ahj.2004.11.015
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- A Comparison of Rate Control and Rhythm Control in Patients with Atrial FibrillationNew England Journal of Medicine, 2002
- Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial InfarctionCirculation, 2002
- Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagulant Therapy in Atrial FibrillationStroke, 2001
- Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial FibrillationCirculation, 2000
- Bleeding During Antithrombotic Therapy in Patients With Atrial FibrillationArchives of Internal Medicine, 1996
- Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor strokeThe Lancet, 1993
- Canadian atrial fibrillation anticoaguiation (CAFA) studyJournal of the American College of Cardiology, 1991
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991
- Stroke Prevention in Atrial Fibrillation Study. Final results.Circulation, 1991